Salute e Benessere

Oculis updates share capital for its existing at-the-market offering program

The New Shares were issued in relation to the sales agreement between the Company and Leerink Partners LLC (”Leerink Partners”) entered into on May 8, 2024, with respect to an at-the-market (“ATM”) offering program. Under the ATM offering program, the Company may offer and sell, from time to time at its sole discretion, ordinary shares of the Company having an aggregate offering price of up to $100 million through Leerink Partners as its sales agent. The New Shares have not been sold under...
Nasdaq GlobeNewswire
31/01/2025

Bavarian Nordic – Completion of Share Buy-Back Program

COPENHAGEN, Denmark, January 31, 2025– Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on January 9, 2025, has now been completed, reaching an aggregate amount of approximately DKK 150 million as planned. Bavarian Nordic will hold the shares bought back as treasury stock, for the purpose of adjusting the capital structure and meeting the long-term obligations relating to the Company's share-based incentive programs for the Board...
Nasdaq GlobeNewswire
31/01/2025

Mile High Labs Achieves Milestone in UK Novel Foods Process

LONDON, Jan. 31, 2025 /PRNewswire/ -- Mile High Labs (MHL), a global leader in hemp-derived cannabinoid ingredients and finished products, is proud to announce its progression to the Risk Management Phase of the UK Novel Foods process. This milestone establishes MHL as the first and only hemp-derived CBD manufacturer to reach this advanced stage of regulatory approval, reinforcing its commitment to compliance, quality, and innovation. LONDON , Jan. 31, 2025 /PRNewswire/ --Mile High...
PR Newswire
31/01/2025

Inside information: Bioretec Ltd. receives CE mark approval for RemeOs™ Trauma…

*RemeOs FT cannulated, RemeOs FL cannulated, RemeOs FC cannulated and RemeOs LAG Solid *RemeOs FT cannulated, RemeOs FL cannulated, RemeOs FC cannulated and RemeOs LAG Solid Further enquiries Alan Donze, CEO, +1 619 977 5285Johanna Salko, CFO, +358 40 754 8172 Certified adviser Nordic Certified Adviser AB, +46 70 551 67 29 Bioretec in brief Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable...
PR Newswire
31/01/2025

EssilorLuxottica: Full-Year 2024 Results Conference Call Invitation

Full-Year 2024 Results Conference Call Invitation Mr FRANCESCO MILLERI, Chairman and Chief Executive Officer, Mr PAUL DU SAILLANT, Deputy Chief Executive Officer, Mr STEFANO GRASSI, Chief Financial Officer, and Mr GIORGIO IANNELLA, Head of Investor Relations, have the pleasure of inviting you to our Full-Year 2024 Results Conference Call on: Wednesday, February 12, 2025, at 6:30 pm CET Dial-in telephone access:If you wish to dial into the conference call, please pre-register at...
Nasdaq GlobeNewswire
31/01/2025

Roche receives FDA approval for the first companion diagnostic to identify…

As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered HER2-ultralow. 1These patients may now be eligible for a targeted treatment, which could significantly improve their outcomes. The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for...
Nasdaq GlobeNewswire
31/01/2025

Interventional Oncology Market to Hit USD 4.24 Billion by 2029 with 9.0% CAGR |…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=203687164 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=203687164 Browse in-depth TOC on "Interventional Oncology Market" 571 - Tables 63 - Figures 455 - Pages Based on devices & consumables,the embolization devices were the largest application segment in interventional oncology market due to crucial role played by such products for minimally invasive...
PR Newswire
31/01/2025

Human Organs-on-Chips Market to Reach USD 1019 Million by 2031 | 31.2% CAGR…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-39D8996/Global_Human_Organs_on_Chips_Market Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-39D8996/Global_Human_Organs_on_Chips_Market Major Factors Driving the Growth of Human Organs-On-Chips Market: The Human Organs-on-Chips Market is poised for substantial growth, driven by the increasing demand for advanced in vitro models that replicate human organ functions for...
PR Newswire
31/01/2025

MintNeuro Wins Three UK Government ARIA Awards to Apply Advanced Chip Technology…

MintNeuro will lead the custom development and integration of low-power, function-specific integrated circuits and systems for each of the three funded projects, aligned with the programme's mission to develop precise, less invasive, and biologically integrated neurotechnologies: MintNeuro will lead the custom development and integration of low-power, function-specific integrated circuits and systems for each of the three funded projects, aligned with the programme's mission to develop…
PR Newswire
31/01/2025

HexClad's "Unidentified Frying Object" Ad Lands At Super Bowl LIX

LOS ANGELES, Jan. 31, 2025 /PRNewswire/ -- HexClad, the most innovative kitchenware brand in the world, today unveiled "Unidentified Frying Object", its first-ever Super Bowl commercial that will air during the big game on February 9. The historic :30 second spot stars culinary icon and HexClad partner Gordon Ramsay, who showcases the brand's "out-of-this-world" technology alongside a surprise cameo appearance by actor and comedian Pete Davidson in an intergalactic kitchen…
PR Newswire
31/01/2025

Accord Healthcare launches Disulfiram in the United Kingdom, indicated as a…

When alcohol is consumed, it is metabolised in the body into acetaldehyde. Disulfiram works by blocking the enzyme which breaks down acetaldehyde. This leads to an increased level of acetaldehyde in the blood causing a number of unpleasant physical reactions including headache, heart palpitations and nausea. The experience of such reactions acts as a deterrent to the further consumption of alcohol. When alcohol is consumed, it is metabolised in the body into acetaldehyde. Disulfiram works by...
PR Newswire
31/01/2025

DRG Is Launching Innovative Traumatic Brain Injury (TBI) Test Panel at MEDLAB in…

DRG's TBI Tests are CE-marked and have been verified to meet CLSI (Clinical and Laboratory Standards Institute) requirements. They are intended for use in a clinical laboratory setting and are indicated for patients aged 18 years or older. DRG's TBI Tests are CE-marked and have been verified to meet CLSI (Clinical and Laboratory Standards Institute) requirements. They are intended for use in a clinical laboratory setting and are indicated for patients aged 18 years or older. To learn more...
PR Newswire
31/01/2025

Unilumin Elevates 2025 CCTV Spring Festival Gala with Cutting-Edge LED Solutions

Unilumin's technology seamlessly integrated AI, XR, digital twin, and virtual production (VP) techniques, expanding the stage beyond physical limits. The opening act, Ruyi Dance, featured a golden serpent brought to life with AR, creating a dynamic visual spectacle. In Yi Ren, Unilumin's UE-powered special effects transformed dancers' movements into poetic ripples, fusing dance and technology. Unilumin's technology seamlessly integrated AI, XR, digital twin, and virtual production (VP)...
PR Newswire
31/01/2025

Update on regulatory review of lecanemab for treatment of early Alzheimer's…

The safety profile of lecanemab reported in clinical practice in the United States, Japan and other countries after launch is consistent with that in the approved labels, and no new safety signals are identified. Eisai believes that the existing information is clear and sufficient, allowing the EC's requests to be addressed and evaluated by the CHMP. Eisai will continue to work closely with the authorities toward approval in the EU. The safety profile of lecanemab reported in clinical…
PR Newswire
31/01/2025

OKYO Pharma Announces Chairman and CEO Acquire Shares

LONDON and NEW YORK, Jan.31, 2025(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, announced today that it has been notified that the Chief Executive Officer, Gary S. Jacob, has purchased 10,000 of the Company's ordinary...
Nasdaq GlobeNewswire
31/01/2025

VANTAGE FOUNDATION PARTNERS WITH SOS CHILDREN'S VILLAGES PHILIPPINES TO EMPOWER…

These villages consist of small family homes, each managed by an SOS mother who provides the children with the attention, love, and care of a real family. The children grow up in these homes alongside their biological siblings (if any) and other children, with the continuous support of caregivers who serve as role models and provide emotional, educational, and psychological guidance. These villages consist of small family homes, each managed by an SOS mother who provides the children with the...
PR Newswire
31/01/2025

Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the…

TOKYO and CAMBRIDGE, Mass., Jan.31, 2025(GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as treatment for early AD (mild cognitive impairment due to Alzheimer's disease (AD) and mild AD) in the European Union.In...
Nasdaq GlobeNewswire
31/01/2025

Announcement of change in the total number of votes in AB SKF

AB SKF does not hold any own shares. AB SKF does not hold any own shares. Aktiebolaget SKF (publ) Information in this press release contains information that AB SKF is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication on31 January 2025at12:00 CET. For further information, please contact:PRESS: Carl Bjernstam, Head of Media Relations tel: 46 31-337 2517; mobile: 46 722-201 893; e-mail:...
PR Newswire
31/01/2025

Augnito Secures Major Enterprise Partnership with Almoosa Health

The agreement will see Augnito's ambient intelligence tool seamlessly integrated with Almoosa's existing Electronic Medical Records (EMR) and Hospital Information System (HIS). This integration will empower hundreds of clinicians to deliver faster, more accurate, and patient centric care. Omni's AI Scribe is proficient with multi-lingual medical dialogue capture (including all Arabic dialects) and efficient data organizing for seamless integration into Electronic Medical Records, among other…
PR Newswire
31/01/2025

Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for…

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old.The virus-like particle (VLP) single-dose chikungunya vaccine is expected to launch in key European markets in the first half of 2025, pending final marketing authorization.COPENHAGEN, Denmark, January 31, 2025– Bavarian Nordic A/S (OMX: BAVA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion...
Nasdaq GlobeNewswire
31/01/2025

Change in number of shares and votes in Immunovia AB (publ)

This information is such information that Immunovia AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, on 31 January 2025 at 10:00 CET. This information is such information that Immunovia AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact...
PR Newswire
31/01/2025

Director/PDMR Shareholding

DXS INTERNATIONAL PLC(AQSE: DXSP)Notification of Director / PDMR DealingDXS INTERNATIONAL PLC The Board of DXS International plc (the “Company” or “DXSP), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems, has received notification that on 30 January, Mr Bob Sutcliffe, the Chairman, purchased 15,000 Ordinary Shares in the Company at a price of 2.9p per share.Following this transaction Mr Sutcliffe and his wife's...
Nasdaq GlobeNewswire
31/01/2025

SKF Year-end report Q4 2024: Strong execution supporting margin resilience

Net sales: SEK 24,725 million (24,438)Organic growth: −3.1% (−1.9%), driven by lower market demand mainly in Europe and China, while Americas and India & Southeast Asia are showing positive sales development.Adjusted operating profit: SEK 2,735 million (2,929). Continued strong price/mix contribution was offset by negative currency effects as well as lower volumes, which also resulted in decreased cost efficiency.Adjusted operating margin: 11.1% (12.0%)Net cash flow from operating…
PR Newswire
31/01/2025

Press Release: Sarclisa is the first anti-CD38 treatment approved in China for…

Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant Approval based on positive results from the IMROZ phase 3 study that demonstrated Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free survival, compared to VRd alone in transplant-ineligible newly diagnosed multiple myeloma Second approval in China in three weeks following the R/R MM...
Nasdaq GlobeNewswire
31/01/2025
Altri  Comunicati